Nicotinamide riboside (NR): adverse events and evidence limits
In four-week NR-SAFE, oral NR chloride in Parkinson’s disease was accompanied by mild headache, nausea and dyspepsia; causal attribution varied. [1]
In a retrospective series of eight adults receiving IV NR over four days, tingling and cramps occurred. One infusion paused for menstrual-associated cramping, described inconsistently as severe/mild. These compounded-product observations do not establish oral NR risks. [2]
What the studies reported
| Effect | Model or participants | How often or as described | Source |
|---|---|---|---|
| Headache | Patients with Parkinson’s disease, oral NR chloride, four-week NR-SAFE trial | Observed, mild; causal attribution varied; no percentage given | [1] |
| Nausea | The same patients | Observed, mild; no frequency given | [1] |
| Dyspepsia | The same patients | Observed, mild; no frequency given | [1] |
| Tingling | Eight adults, intravenous NR over four days (retrospective series) | Occurred; these observations do not establish oral NR risks | [2] |
| Cramps | The same adults | Occurred; one infusion paused for menstrual-associated cramping, described inconsistently as severe/mild | [2] |
References
- Haakon Berven et al. (2023). NR-SAFE: a randomized, double-blind safety trial of high dose nicotinamide riboside in Parkinson's disease https://doi.org/10.1038/s41467-023-43514-6.
- Kirsten Reyna et al. (2026). Intravenous infusion of nicotinamide adenine dinucleotide (NAD+) versus nicotinamide riboside (NR): a retrospective tolerability pilot study in a real-world setting https://doi.org/10.3389/fragi.2026.1652582.